WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006088920) AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088920    International Application No.:    PCT/US2006/005266
Publication Date: 24.08.2006 International Filing Date: 14.02.2006
IPC:
C07D 401/12 (2006.01), C07D 409/14 (2006.01), C07D 401/14 (2006.01), C07D 405/14 (2006.01), C07D 211/58 (2006.01), C07D 417/14 (2006.01), C07D 413/14 (2006.01), A61K 31/497 (2006.01), A61P 31/00 (2006.01), A61P 29/00 (2006.01)
Applicants: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US) (For All Designated States Except US).
PHARMACOPEIA, INC. [US/US]; 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (US) (For All Designated States Except US).
WONG, Michael, K., C. [CA/US]; (US) (For US Only).
SHU, Youheng [CN/US]; (US) (For US Only).
YU, Wensheng [CN/US]; (US) (For US Only).
ROSENBLUM, Stuart, B. [US/US]; (US) (For US Only).
KOZLOWSKI, Joseph, A. [US/US]; (US) (For US Only).
MCGUINNESS, Brian, F. [US/US]; (US) (For US Only).
SHAO, Yuefei [CN/US]; (US) (For US Only).
HOBBS, Douglas, W. [US/US]; (US) (For US Only)
Inventors: WONG, Michael, K., C.; (US).
SHU, Youheng; (US).
YU, Wensheng; (US).
ROSENBLUM, Stuart, B.; (US).
KOZLOWSKI, Joseph, A.; (US).
MCGUINNESS, Brian, F.; (US).
SHAO, Yuefei; (US).
HOBBS, Douglas, W.; (US)
Agent: BANERJEE, Krishna, G.; Schering-Plough Corporation, 2000 Galloping Hill Road, Patent Dept. K-6-1 1990, Kenilworth, New Jersey 07033-0530 (US)
Priority Data:
60/653,339 16.02.2005 US
Title (EN) AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY
(FR) PYRIDYLE A LIAISON AMINE ET PIPERAZINE-PIPERIDINES SUBSTITUEES A ACTIVITE AGONISTE CXCR3
Abstract: front page image
(EN)The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formual should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
(FR)La présente invention a trait à un composé, ou enantiomères, stéréoisomères, rotamères, tautomères, racémates ou prodrogue dudit composé, ou des sels, solvates ou esters dudit composé, ou dudit prodrogue, ledit composé étant représenté par la formule générale (I), et les sels, solvates et esters de celui-ci pharmaceutiquement acceptables. L'invention a également trait à un procédé de traitement de maladies liés à la chimiokine, tel que, la thérapie palliative, la thérapie curative, la thérapie prophylactique de certaines maladies et conditions telles que des maladies inflammatoires (des exemples non limitatifs comprennent, le psoriasis), des maladies auto-immunes (des exemples non limitatifs comprennent le rejet de greffe allogénique, le rejet de xénogreffe) des maladies infectieuses (par exemple, la lèpre tuberculoïde), des éruptions médicamenteuses fixes, des réactions d'hypersensibilité retardées cutanées, l'inflammation ophtalmique, le diabète insulino-dépendant, la méningite virale et des tumeurs mettant en oeuvre un composé de formule (I).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)